With positive data from a Phase IIa trial in hand, Actelion AG plans to move directly into a Phase III morbidity/mortality trial of its first-in-class oral prostacyclin (PGI2) receptor agonist in pulmonary arterial hypertension (PAH) before year-end. (BioWorld International)

LONDON - Recent developments stemming from the sequencing of the human genome represent a unique opportunity for real advances in medical care, and the UK government and National Health Service (NHS) must take steps to ensure that those are realized, noted a report published last week by the House of Lords Science and Technology Committee. (BioWorld International)